Back to top
more

Adverum Biotechnologies (ADVM)

(Delayed Data from NSDQ)

$9.19 USD

9.19
798,696

-0.20 (-2.13%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $9.21 +0.02 (0.22%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Adverum Biotechnologies (ADVM) and Aurora Cannabis Inc. (ACB) have performed compared to their sector so far this year.

Down -24.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)

by Zacks Equity Research

Adverum Biotechnologies (ADVM) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Are Medical Stocks Lagging Adverum Biotechnologies (ADVM) This Year?

by Zacks Equity Research

Here is how Adverum Biotechnologies (ADVM) and Cigna (CI) have performed compared to their sector so far this year.

How Adverum (ADVM) Stock Stands Out in a Strong Industry

by Zacks Equity Research

Adverum (ADVM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Down -28.72% in 4 Weeks, Here's Why Adverum Biotechnologies (ADVM) Looks Ripe for a Turnaround

by Zacks Equity Research

The heavy selling pressure might have exhausted for Adverum Biotechnologies (ADVM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -29.25% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Adverum Biotechnologies (ADVM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Adverum Biotechnologies (ADVM) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.

Here's Why You Should Invest in Adverum (ADVM) Stock Now

by Zacks Equity Research

Here, we discuss some reasons why buying Adverum Biotechnologies (AQST) stock now may turn out to be a prudent move.

Is Adial Pharmaceuticals (ADIL) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Adial Pharmaceuticals, Inc. (ADIL) and Adverum Biotechnologies (ADVM) have performed compared to their sector so far this year.

Adverum (ADVM) Doses First Patient in the Mid-Stage wAMD Study

by Zacks Equity Research

Adverum (ADVM) initiates dosing in the phase II LUNA study, currently investigating its lead product candidate ixoberogene soroparvovec for wet age-related macular degeneration.

Adverum (ADVM) Completes IND Amendment for Gene Therapy Study

by Zacks Equity Research

Adverum (ADVM) completes IND amendment with the FDA for initiating the phase II LUNA study on its gene therapy candidate, ADVM-022, for treating wet-age-related macular degeneration. Stock up.

Adverum (ADVM) Up on FDA Feedback for Gene Therapy Study

by Zacks Equity Research

Adverum (ADVM) to submit IND amendment to the FDA by mid-2022 for starting a mid-stage study on its gene therapy candidate ADVM-022 for treating wet AMD eye disorder.

Should You Buy Adverum Biotechnologies (ADVM) Ahead of Earnings?

by Zacks Equity Research

Adverum Biotechnologies (ADVM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Adverum Biotechnologies (ADVM) Might Surprise This Earnings Season

by Zacks Equity Research

Adverum Biotechnologies (ADVM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

What's in Store for Harrow Health (HROW) in Q2 Earnings?

by Zacks Equity Research

Harrow Health (HROW) Q2 results are likely to reflect growth coming from the launch of Visionology, the company's direct-to-consumer eyecare platform.

BioNTech (BNTX) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

On BioNTech's (BNTX) second-quarter earnings call, investors' focus will be on sales number of BNT162b2, its COVID-19 vaccine, developed in partnership with Pfizer.

Novavax (NVAX) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

On Novavax's (NVAX) upcoming second-quarter earnings call, investor focus is likely to be on the company's progress with its COVID-19 vaccine candidate, NVX-CoV2373.

Bionano (BNGO) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Bionano Genomics (BNGO) is likely to provide updates on earnings and revenues when it reports second-quarter 2021 results.

Adverum Biotechnologies (ADVM) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Adverum Biotechnologies (ADVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Are Options Traders Betting on a Big Move in Adverum (ADVM) Stock?

by Zacks Equity Research

Investors need to pay close attention to Adverum (ADVM) stock based on the movements in the options market lately.

Dr. Reddy's (RDY) Q4 Earnings Decline Y/Y, Sales Increase

by Zacks Equity Research

Dr. Reddy's (RDY) earnings decline while sales grow year over year in fourth-quarter fiscal 2021.

Adverum Biotechnologies (ADVM) is Oversold: Can It Recover?

by Zacks Equity Research

Adverum Biotechnologies (ADVM) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

Adverum Biotechnologies (ADVM) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of 23.68% and 1530.44%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Is the Options Market Predicting a Spike in Adverum Biotechnologies (ADVM) Stock?

by Zacks Equity Research

Investors need to pay close attention to Adverum Biotechnologies (ADVM) stock based on the movements in the options market lately.

Adverum Biotechnologies (ADVM) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of -21.88% and -100.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?